Development and validation of a LC/TOF MS method for the determination of carboplatin and paclitaxel in nanovesicles

Analytical and Bioanalytical Chemistry

Volumn 406, Issue 11, 2014, Pages 2659-2667

  Mo, Jingxin ^a   Eggers, Paul K ^b   Raston, Colin L ^c   Lim, Lee Yong ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Carboplatin; Co loaded nanovesicles; Fetal bovine serum; LC TOF MS; Paclitaxel; Simultaneous determination

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; PRECIPITATION (CHEMICAL);

CARBOPLATIN; FETAL BOVINE SERUM; LC/TOF MS; NANO-VESICLES; PACLITAXEL; SIMULTANEOUS DETERMINATIONS;

QUALITY CONTROL;

ANIMALIA; BOVINAE; CARNATION LATENT VIRUS;

ANTINEOPLASTIC AGENT; CARBOPLATIN; DRUG CARRIER; PACLITAXEL;

ANIMAL; BLOOD; BOVINAE; CHEMISTRY; DRUG STABILITY; EVALUATION STUDY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEDICINAL CHEMISTRY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CATTLE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DRUG CARRIERS; DRUG STABILITY; HUMANS; MASS SPECTROMETRY; PACLITAXEL;

EID: 84898047902     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-7684-0     Document Type: Article

References (22)

1. Cohen MH, Shen YL, Keegan P, Pazdur R (2012) FDA drug approval summary: bevacizumab (Avastin (R)) as treatment of recurrent glioblastoma multiforme (vol 14, pg 1131, 2009). Oncologist 17(11):1482-1482
2. Panchagnula R (1998) Pharmaceutical aspects of paclitaxel. Int J Pharm 172(1-2):1-15
3. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665-7
4. Huang Y, Sheikh MS, Fornace AJ, Holbrook NJ (1999) Serine protease inhibitor TPCK prevents taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 18(23):3431-3439
5. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R (1993) Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15:141-7
6. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44(4):1693-7
7. Villarino N, Cox S, Yarbrough J, Martin-Jimenez T (2010) Determination of carboplatin in canine plasma by high-performance liquid chromatography. Biomed Chromatogr 24(8):908-913
8. Benaji B, Dine T, Luyckx M, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Gressier B, Cazin JC (1994) Stability and compatibility of cisplatin and carboplatin with Pvc infusion bags. J Clin Pharm Ther 19(2):95-100
9. Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U (1999) Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit 21(6):631-7
10. Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal 24(1):1-10
11. Curis E, Provost K, Bouvet D, Nicolis I, Crauste-Manciet S, Brossard D, Benazeth S (2001) Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS. J Synchrotron Radiat 8(Pt 2):716-8
12. Bales JR, Coulson CJ, Gilmour DW, Mazid MA, Neidle S, Kuroda R, Peart BJ, Ramsden CA, Sadler PJ (1983) The preparation and isomerization of platinum metronidazole complexes - x-ray crystal and molecular structures of Cis and trans-dichlorobis[1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole]-platinum(Ii). J Chem Soc Chem Comm 8:432-433
13. Jiang HL, Zhang Y, Ida M, LaFayette A, Fast DM (2011) Determination of carboplatin in human plasma using hybrid SPE-precipitation along with liquid chromatography-tandem mass spectrometry. J Chromatogr B 879(22):2162-2170
14. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Farmen RH (1993) High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (taxol) in human plasma. J Chromatogr 621(2):231-8
15. Kim SC, Yu J, Lee JW, Park ES, Chi SC (2005) Sensitive HPLC method for quantitation of paclitaxel (Genexol (R)) in biological samples with application to preclinical pharmacokinetics and biodistribution. J Pharm Biomed Anal 39(1-2):170-176
16. Tong X, Zhou J, Tan Y (2006) Determination of paclitaxel in rat plasma by LC-MS-MS. J Chromatogr Sci 44(5):266-71
17. Tan Y, Zhou JP, Tong XY, Feng F (2006) LC-MS/MS for determination of paclitaxel in rat tissues: application to a biodistribution study of paclitaxel nanoliposome modified by PEO-PPO-PEO triblock copolymers. Anal Lett 39(7):1349-1363
18. Suno M, Ono T, Iida S, Umetsu N, Ohtaki K, Yamada T, Awaya T, Satomi M, Tasaki Y, Shimizu K, Matsubara K (2007) Improved high-performance liquid chromatographic detection of paclitaxel in patient's plasma using solid-phase extraction, and semi-micro-bore C-18 separation and UV detection. J Chromatogr B 860(1):141-144
19. Whitaker G, Lillquist A, Pasas SA, O'Connor R, Regan F, Lunte CE, Smyth MR (2008) CE-LIF method for the separation of anthracyclines: application to protein binding analysis in plasma using ultrafiltration. J Sep Sci 31(10):1828-33
20. Mittal A, Chitkara D, Kumar N (2007) HPLC method for the determination of carboplatin and paclitaxel with cremophorEL in an amphiphilic polymer matrix. J Chromatogr B Anal Technol Biomed Life Sci 855(2):211-9
21. Eggers PK, Becker T, Melvin MK, Boulos RA, James E, Morellini N, Harvey AR, Dunlop SA, Fitzgerald M, Stubbs KA, Raston CL (2012) Composite fluorescent vesicles based on ionic and cationic amphiphilic calix[4]arenes. RSC Adv 2(15):6250-6257
22. US FDA, U. D. o. H. a. H. S., FDA (2001) Center for Drug Evaluation and Research, Rockville, MD, USA http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf